You are here

P&T® Journal contents for December 2008


Health care professionals must consider drug-related adverse events along with efficacy when they prescribe medications. In explaining such concepts as statistical significance and magnitude of effect, the author suggests how indirect comparisons of studies can be used to help guide treatment decisions, especially if patients are taking other agents and combination therapy.
Stephen V. Faraone, PhD
Meeting Highlights
Presentations included voreloxin for acute myelogenous leukemia; azacytidine (Vidaza) and decitabine (Depo-Cyt) for myelodysplastic syndromes; lenalidomide (Revlimid) for lymphoma; and dasatinib (Sprycel), nilotinib (Tasigna), and other investigational agents for chronic myelogenous leukemia.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Topics discussed at the ophthalmic meeting included medications for dry eye and for diabetes-related conditions. The Onmark Forum focused on the anticipated need for collaboration between oncologists and adjunctive personnel because of a workforce gap; online information gathering; and standardizing procedures.
Walter Alexander
Continuing Education Credit
Obesity can have deleterious effects on health, often leading to diabetes and ­cardiovascular disease. Bariatric surgery, diet and behavior modification, and ­current and investigational drug therapies are some of the tools that are available now to help the overweight patient population.
Sarah R. Erlanger, PharmD, and Emily A. Henson, PharmD


David Nash, MD, MBA, discusses Pharmaceutical Industry Profile 2008, which documents the growth in spending and in product development by drug companies during the past two years.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains how hospital workers can prevent tragic outcomes by carefully labeling all medication containers and solutions.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses new rules that might allow consumers to sue pharmaceutical companies in state courts over drug labeling.
Stephen Barlas
From Banzel to Vimpat, P&T presents the latest FDA approvals, new indications, recalls, and industry updates.
Drug Forecast
Authors Yero and Rey review tetrabenazine (Xenazine) for Huntington’s chorea.
Tatiana Yero, PharmD, BS, and Jose A. Rey, PharmD, BCPP